| Patents for A61P 3 - Drugs for disorders of the metabolism (129,789) |
|---|
| 07/29/2009 | EP2083006A1 Oxadiazolones, processes for their preparation and their use as pharmaceuticals |
| 07/29/2009 | EP2082743A2 Inhibitors of GSK-3 and crystal structures of GSK-3beta protein and protein complexes |
| 07/29/2009 | EP2081963A2 Methods for reducing phosphate absorption |
| 07/29/2009 | EP2081957A1 Peg modified exendin or exendin analog and compositions and use thereof |
| 07/29/2009 | EP2081894A1 1h-indole-2-carboxylic acid derivatives useful as ppar modulators |
| 07/29/2009 | EP2081647A2 Method of preventing or treating metabolic syndrome |
| 07/29/2009 | EP2081600A1 Combination of nmda- receptor ligand and a compound with 5-ht6 receptor affinity |
| 07/29/2009 | EP2081597A1 Long-term enteral feed for maintenance |
| 07/29/2009 | EP2081569A2 Combination therapy with sglt-2 inhibitors and their pharmaceutical compositions |
| 07/29/2009 | EP2081564A2 Use of citrulline for treating undernutrition conditions |
| 07/29/2009 | EP1926712B1 6-substituted 2,3,4,5-tetrahydro-1h-benzo[d]azepines as 5-ht2c receptor agonists |
| 07/29/2009 | EP1841734B1 5-aminoindole derivatives |
| 07/29/2009 | EP1781116A4 Natural sweetener |
| 07/29/2009 | EP1686119B1 Pyrimidine-5-one derivatives as LDL-PLA2 inhibitors |
| 07/29/2009 | EP1641791B1 3-(guanidinocarbonyl)heterocycle derivatives, preparation process and intermediates of this process, their use as medicaments, and pharmaceutical compositions including them |
| 07/29/2009 | EP1601671B1 Cycloalkyl derivatives comprising bioisosteric carboxylic acid groups, method for the production thereof, and use thereof as a medicament |
| 07/29/2009 | EP1411895B2 Oral pharmaceutical composition comprising an active principle capable of being subjected to high effect during its first passage through the intestine |
| 07/29/2009 | EP1409468B9 Guanidinobenzamides as mc4-r agonists |
| 07/29/2009 | EP1397357B1 Polymorphic forms of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl)piperazine hydrochloride |
| 07/29/2009 | EP1363876B1 Glucocorticoid receptor modulators |
| 07/29/2009 | EP1293567B1 Ligand to gpr8 and dna thereof |
| 07/29/2009 | EP1292676B1 Mutation associated with epilepsy |
| 07/29/2009 | EP1261601B1 Substituted indoles for modulating nfkb activity |
| 07/29/2009 | EP1075191B2 Phytosterol compositions |
| 07/29/2009 | CN101492416A Compounds effecting glucokinase |
| 07/29/2009 | CN100519552C Pyrazole compounds |
| 07/29/2009 | CN100519550C 2-oxo-indole compound having a functtion of inhibiting glycogen synthase kinase-3 |
| 07/29/2009 | CN100519549C Pyrimidine derivatives and pharmaceutical compositions containing the compounds |
| 07/29/2009 | CN100519539C N3 alkylated benzimidazole derivatives as MEK inhibitors |
| 07/29/2009 | CN100519527C Inhibitors of histone deacetylase |
| 07/29/2009 | CN100519526C Azabicyclo derivatives as muscarinic receptor antagonists |
| 07/29/2009 | CN100518819C Medical components comprising human parathyroid hormone and medicinal compositions for nasal administration containing the components |
| 07/29/2009 | CN100518806C Medicinal composition |
| 07/29/2009 | CN100518741C Pregnane steroids for use in the treatment of cns dysfunction |
| 07/29/2009 | CN100518736C Indol-4 sulfonamide derivatives, their preparation and their use 5-ht-6 as modulators |
| 07/29/2009 | CN100518735C Derivatives of tryptamine and analogous compounds, and pharmaceutical formulations containing them |
| 07/29/2009 | CN100518733C Compositions for the treatment and prevention of diabetes mellitus |
| 07/28/2009 | US7566782 Process for the preparation of rosuvastatin |
| 07/28/2009 | US7566781 melanin concentrating hormone receptor antagonist; preventing or treating vascular system diseases, nervous system disorders, metabolic disorders, urogenital diseases, respiratory diseases disorders; N-(2-ethyl-3-methylimidazo[1,2-a]pyridin-6-yl)-3-fluoro-4-(pyridin-2-ylmethoxy)benzamide |
| 07/28/2009 | US7566767 Synthetic peptides and methods of use for autoimmune disease therapies |
| 07/28/2009 | US7566734 Imidazolyl derivatives |
| 07/28/2009 | US7566720 9-[2-(1H-indol-3-yl)ethyl]-2-pyridin-4-yl-6,7,8,9-tetrahydro-4H-pyrimido[1,2-a]pyrimidin-4-one; glycogen synthase kinase 3 beta inhibitors; nerve growth factors; neurodegenerative diseases; Alzheimer's disease; Parkinson's disease; tauopathies; stroke; vision defects;antidiabetic agent; anticarcinogenic |
| 07/28/2009 | US7566715 Substituted sulfonamide compounds useful for the prophylaxis and treatment of conditions relating to obesity, type II diabetes and/or disorders of the central nervous system |
| 07/28/2009 | US7566707 For example, 2-[3-(Tert-butyloxycarbonylamino)-piperidin-1-yl]-3-(2-butyn-1-yl)-5-[(dibenzo[b,f][1,4]-oxazepin-11-yl)methyl]-3,5-dihydro-imidazo[4,5-d]pyridazin-4-one; inhibiting effect on activity of the enzyme dipeptidylpeptidase-IV; use in treatment of diabetes mellitus, arthritis, obesity |
| 07/28/2009 | US7566699 Fused heterocyclic derivative, medicinal composition containing the same, and medicinal use thereof |
| 07/28/2009 | US7566698 Extracted from plants such as Ningxia Lycium barbarum L. and/or Lycium chinense Mill; glucosyltransferases, cellulases; provitamin C with improved stability and bioavailability; ultraviolet damage protector; antiwrinkling; whitening |
| 07/28/2009 | US7566695 Multimeric apoprotein agonists |
| 07/28/2009 | US7566694 Anti-pathogen treatments |
| 07/28/2009 | CA2315235C Phenylaminoalkylcarboxylic acid derivatives and medicinal compositions containing the same |
| 07/23/2009 | WO2009091885A1 Health beverages comprising cinnamon extract and methods of making and using the same |
| 07/23/2009 | WO2009091634A1 Crystalline 2-(4-cyclopropanesulphonyl-phenyl)-n-pyrazin-2-yl-3-(tetrahydropyran-4-yl)-propionamide |
| 07/23/2009 | WO2009091538A2 Pharmaceutical composition comprising epa and dha for treating hypertriglyceridemia and hypercholesterolemia |
| 07/23/2009 | WO2009091341A1 Novel peptides and protein and uses thereof |
| 07/23/2009 | WO2009091082A1 Combination therapy comprising sglt inhibitors and dpp4 inhibitors |
| 07/23/2009 | WO2009091014A1 Phenyl acetamide derivative |
| 07/23/2009 | WO2009090623A1 Tetrahydrocyclopenta[c]acridine derivatives as kinase inhibitors and biological applications thereof |
| 07/23/2009 | WO2009090210A2 Combination of metformin and an mtp inhibitor |
| 07/23/2009 | WO2009071690A3 5,6-disubstituted oxindole-derivatives and use thereof for treating vasopressine-dependent diseases |
| 07/23/2009 | WO2009071689A3 5-halogen-substituted oxindole derivatives and use thereof for treating vasopressine-dependent diseases |
| 07/23/2009 | WO2009071678A3 Morpholine derivatives as antiobesity agents |
| 07/23/2009 | WO2009067182A3 Phospholipid compositions and uses thereof |
| 07/23/2009 | WO2009063061A3 Aryl- and heteroarylcarbonyl derivatives of benzomorphanes and related scaffolds, medicaments containing such compounds and their use |
| 07/23/2009 | WO2009053794A3 The use of a monocyclic monoterpene in manufacturing medicaments for treatment of diabetes |
| 07/23/2009 | WO2009046845A3 Use of a lactoferrin partial peptide peptide as a therapeutic agent |
| 07/23/2009 | WO2009043523A3 Cortistatin 17 and neuropeptide 1 for use as therapeutic agent |
| 07/23/2009 | WO2009040084A3 Use of a peptide as a therapeutic agent |
| 07/23/2009 | WO2009040034A3 Use of a peptide as a therapeutic agent |
| 07/23/2009 | WO2009039973A3 Use of peptide arg-asn-ile-ala-glu-ile-ile-lys-asp-ile-oh or its combination with the peptide asp-arg-gly-asp-ser-oh as a therapeutic agent |
| 07/23/2009 | WO2009033816A3 Use of the combination of thymosin beta 10 and thymosin alpha 1 peptides as a therapeutic agent |
| 07/23/2009 | WO2009033773A3 Use endothelin 2, alone or combined with a nonapeptide, a peptide as a therapeutic agent |
| 07/23/2009 | WO2009033761A3 Use of a fragment of hcv nucleo protein, alone or together with endothelin-3, as a therapeutic agent |
| 07/23/2009 | WO2009031023A3 Pomegranate extracts, nutritional products containing them and their uses |
| 07/23/2009 | WO2009027106A3 Non-invasive in vivo imaging and methods for treating type i diabetes |
| 07/23/2009 | WO2009023664A3 Substituted azepine- and diazepine-sulfonamides useful to inhibit 11beta-hydroxysteroid dehydrogenase type-1 |
| 07/23/2009 | WO2009005671A3 Substituted piperazines as cb1 antagonists |
| 07/23/2009 | WO2008127591A3 Pyrimidinedione derivatives and use thereof |
| 07/23/2009 | WO2008125901A8 2-methylene-1alpha,25-dihydroxy-18,19,21-trinorvitamin d3 and uses thereof |
| 07/23/2009 | WO2008119571A3 Nucleic acid myostatin antagonist aptamers obtained by (mirror- image) selex |
| 07/23/2009 | US20090186931 Dinitropyrazole derivatives, their preparation, and energetic compositions comprising them |
| 07/23/2009 | US20090186928 3-[1-(4-Chlorophenyl)-trans-3-fluorocyclobutyl]-4,5-dicyclopropyl-r-4H-1,2,4-triazole anhydrate; Type 2 diabetes, hyperglycemia, obesity, dyslipidemia, hypertension, and cognitive impairment |
| 07/23/2009 | US20090186925 Nicotinic acid compositions for treating hyperlipidemia and related methods therefor |
| 07/23/2009 | US20090186921 Azacyclic compounds |
| 07/23/2009 | US20090186914 Ethyl (2S)-2-[(4,4-dimethyl-3-oxo-1-cyclobutenyl)amino]-3-[(4-([2,7]naphthyridin-1-yloxy)phenyl]propanoate; compounds can inhibit the binding of integrins to their ligands and are of use in the prophylaxis and treatment of immuno or inflammatory disorders |
| 07/23/2009 | US20090186908 Use of 3-hydroxy-3-methylglutaryl coenzym a reductase inhibitors for the manufacture of a medicament for the treatment of diabetic neuropathy |
| 07/23/2009 | US20090186906 N-((S)-4,4-dimethyl-1-oxo-1-((3aS,6aR)-3-oxo-dihydro-2H-furo[3,2-b]pyrrol-4(5H6H, 6aH)-yl)pentan-2-yl)-4-(4-methylpiperazin-1-yl)benzamide; treatment of a disease selected from osteoporosis, Paget's disease, Chagas's disease, malaria, gingival diseases, hypercalaemia, metabolic bone disease, bone cancer |
| 07/23/2009 | US20090186895 Ethers, secondary amines and derivatives thereof as modulators of the 5-ht2a serotonin receptor useful for the treatment of disorders related thereto |
| 07/23/2009 | US20090186894 N-Substituted-Heterocycloalkyloxybenzamide Compounds and Methods of Use |
| 07/23/2009 | US20090186891 Organic compounds |
| 07/23/2009 | US20090186882 Cgrp receptor antagonists |
| 07/23/2009 | US20090186881 1(R)-1-(4-methyl-2-oxo-2,3-dihydro-benzoxazol-6-ylmethyl)-2-oxo-2-[4-(tetrahydropyran-4-yl)-piperazin-1-yl]-ethyl 4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl); calcitonin gene related peptide antagonist; analgesic, antidiabetic agent; migraine or cluster headaches, non-insulin-dependent diabetes |
| 07/23/2009 | US20090186871 Tyrosine kinase inhibitors |
| 07/23/2009 | US20090186870 Therapeutic Agents - 802 |
| 07/23/2009 | US20090186856 Micronutrient phosphates as dietary and health supplements |
| 07/23/2009 | US20090186819 Formulation of insulinotropic peptide conjugates |
| 07/23/2009 | US20090186818 Therapeutic Method for Glycaemic Control |
| 07/23/2009 | US20090186813 Chronic treatment regimen using glucagon-like insulinotropic peptides |
| 07/23/2009 | US20090186807 Zinc-free and low-zinc insulin preparations having improved stability |
| 07/23/2009 | US20090186806 Truncated Activin Type II Receptor and Methods of Use |
| 07/23/2009 | US20090186120 Process to lose weight, drain unwanted body fats and other toxins |
| 07/23/2009 | US20090186110 Guava extract |